How to store Semaglutide
A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
Also called: Ozempic, Wegovy, Wegovy HD, Wegovy FlexTouch, Rybelsus, oral semaglutide, NN9535, NN9924.
GLP-1 / GIP / glucagon agonists · GLP-1 receptor agonist · Evidence: Approved drug.
Comes as: Ready-to-use single-dose pens and prefilled syringes, Ready-to-use multidose pens, Oral tablets with formulation-specific strengths.
Mixed with: None for approved pens, syringes or tablets. Do not add water..
- Wegovy single-dose pen or syringe: before cap removal, up to 28 days at 8–30°C; protect from light.
- Discard single-dose devices after use. Remove each needle from multidose pens; never share pens.
- For reported 5/10 mg powder vials and 2 mL water, see the community reports. No validated home-mixing storage life was found.
- Compounded products need their own concentration, beyond-use date and storage instructions; pen limits do not transfer.
Before mixing: US injections: refrigerate at 2–8°C; do not freeze. Tablets: 20–25°C, dry, in the original bottle.
After mixing: No mixing for approved products. Used Ozempic or Wegovy FlexTouch pens: 56 days refrigerated or at 15–30°C.
Wegovy single-dose pens: keep at 2-8 C in the carton; do not freeze. Before cap removal, up to 28 days at 8-30 C is allowed; discard after use.
Related to Semaglutide
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Liraglutide: A daily GLP-1 injection approved for weight management and type 2 diabetes.
- Dulaglutide: A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.
- Exenatide: An older GLP-1 with twice-daily and weekly forms, now widely discontinued.
- Cagrilintide: An unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms.
Sources
- Canada approves first generic semaglutide for weight loss, 2026
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA · 2026
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, FDA · 2026
- FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications, FDA · 2026
- FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s, 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- First GLP-1 tablet for weight loss approved in the UK, 2026
- Ozempic injection US prescribing information, July 2026; DailyMed Set ID 42bdd912-2393-44c4-b7e0-47672ca28991, 2026
- Rybelsus, INN-semaglutide, 2026
- Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity, 2026
- The 2026 Monitoring Program, World Anti-Doping Agency · 2026
- These highlights do not include all the information needed to use RYBELSUS ® and OZEMPIC® tablets safely and effectively. See full prescribing information for RYBELSUS and OZEMPIC tablets. RYBELSUS (semaglutide) tablets, for oral use OZEMPIC (semaglutide) tablets, for oral use Initial U.S. Approval: 2017, 2026
- Wegovy semaglutide prescribing information: injection strengths, DailyMed · 2026
- WEGOVY- semaglutide injection, solution WEGOVY- semaglutide tablet, DailyMed · DailyMed · 2026
- Wegovy, INN-semaglutide, 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.